KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Shares Outstanding (Diluted Average) (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Shares Outstanding (Diluted Average) for 12 consecutive years, with $79.2 million as the latest value for Q3 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 1.95% to $79.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $79.2 million through Sep 2025, up 1.95% year-over-year, with the annual reading at $77.9 million for FY2024, 16.45% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q3 2025 was $79.2 million at Xenon Pharmaceuticals, roughly flat from $79.0 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $79.2 million in Q3 2025, with the low at $39.5 million in Q2 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $64.7 million, with a median of $65.8 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) surged 45.65% in 2022, then grew 1.41% in 2025.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $43.6 million in 2021, then soared by 38.77% to $60.5 million in 2022, then increased by 10.48% to $66.9 million in 2023, then grew by 16.45% to $77.9 million in 2024, then increased by 1.74% to $79.2 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $79.2 million, $79.0 million, and $78.7 million for Q3 2025, Q2 2025, and Q1 2025 respectively.